Comparative Pharmacology
Head-to-head clinical analysis: INFASURF PRESERVATIVE FREE versus SURFAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFASURF PRESERVATIVE FREE versus SURFAXIN.
INFASURF PRESERVATIVE FREE vs SURFAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Infasurf (calfactant) is a natural bovine lung extract containing phospholipids (primarily dipalmitoylphosphatidylcholine, DPPC) and surfactant-associated proteins B and C. It reduces alveolar surface tension, preventing end-expiratory collapse and stabilizing alveoli, thereby improving lung compliance and gas exchange.
SURFAXIN (lucinactant) is a synthetic pulmonary surfactant that reduces surface tension at the air-liquid interface in the alveoli, preventing alveolar collapse and improving lung compliance and gas exchange. It contains phospholipids and surfactant protein B analog.
Not applicable; Infasurf Preservative Free is an intratracheal suspension indicated only for neonatal respiratory distress syndrome (RDS).
Intratracheal administration: 105 mg phospholipids per kg birth weight (1.5 mL/kg of 35 mg/mL suspension) every 12 hours up to 3 doses total.
None Documented
None Documented
Terminal half-life in preterm infants: 10-17 hours; clearance correlates with lung maturation and surfactant recycling.
Not applicable; Surfaxin is not systemically absorbed. Local pulmonary half-life is not clinically relevant.
Primarily cleared by alveolar macrophages and lung surfactant turnover; minimal renal or biliary excretion (<1%).
Surfaxin (lucinactant) is administered intratracheally and acts locally in the lungs. There is no significant systemic absorption; therefore, excretion pathways are not applicable. The phospholipid components are metabolized and recycled in the lung.
Category C
Category C
Pulmonary Surfactant
Pulmonary Surfactant